Skip to main content
Quest Diagnostics

Pharmacogenomics

Help reduce trial-and-error prescribing and help improve outcomes

Our Pharmacogenomics Panel analyzes high-evidence genes known to influence drug metabolism

Every patient metabolizes medications differently. Variants in specific genes can significantly alter how a drug is absorbed, activated, or broken down—leading to altered efficacy or increased risk of adverse effects.

Adverse drug responses are a leading cause of preventable harm

A lifelong resource for clinical decision-making

Because PGx testing analyzes germline DNA, the results remain valid for life.4 As medication regimens evolve, the information provided can support safer prescribing decisions at every stage of care. Combined with clinical judgment and patient-specific factors (eg, age, comorbidities, concurrent therapies), PGx testing provides a foundation for more informed, personalized treatment.

Quest Pharmacogenomics panels

A lifelong resource for clinical decision-making

Because PGx testing analyzes germline DNA, the results remain valid for life.4 As medication regimens evolve, the information provided can support safer prescribing decisions at every stage of care. Combined with clinical judgment and patient-specific factors (eg, age, comorbidities, concurrent therapies), PGx testing provides a foundation for more informed, personalized treatment.

Actionable insights across multiple therapeutic areas in a single panel

Both pharmacogenomics offerings from Quest Diagnostics analyze genes with clinically actionable pharmacogenetic associations supported by insights from expert groups like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and ClinPGx to help inform decisions across a broad range of clinical areas in a single test.

Cardiology

Genes associated with drugs in classes such as statins, anticoagulants, and beta-blockers

Neurology, psychiatry, and pain

Genes associated with drugs in classes such as antidepressants, opioids, anti-seizure

Oncology

Genes associated with drugs in classes such as chemotherapeutic agents and antiemetics

Gastroenterology

Genes associated with drugs in classes such as immunosuppressants and proton pump inhibitors

Infectious disease

Genes associated with drugs in classes such as antiretrovirals

Help streamline care and reduce cost with PGx testing

By identifying how patients are likely to metabolize medications before treatment begins, pharmacogenomics testing helps reduce trial-and-error prescribing and avoid costly adverse drug events. The result? More efficient prescribing decisions, improved outcomes, and fewer care delays.


Read our white paper to explore how health systems are leveraging PGx to enhance care quality, minimize risk, and control costs across a wide range of therapeutic areas.

Download the white paper
Thumbnail image of Pharmacogenomics white paper

A lifelong resource for clinical decision-making

Because PGx testing analyzes germline DNA, the results remain valid for life.4 As medication regimens evolve, the information provided can support safer prescribing decisions at every stage of care. Combined with clinical judgment and patient-specific factors (eg, age, comorbidities, concurrent therapies), PGx testing provides a foundation for more informed, personalized treatment.

Comprehensive panels with reporting structures designed to fit clinical needs

Test codes  Test names Genes  Sample specifications  Turnaround time
14272  Pharmacogenomics Panels ABCG2
CYP2B6 
CYP2C9  
CYP2C19
CYP2D6   
CYP3A4 
CYP3A5  
CYP4F2  
DPYD
F5  
HLA-A*31:01		 HLA-B*15:02 
HLA-B*57:01 
HLA-B*58:01   
IFNL3
NAT2 
NUDT15
SLCO1B1  
TPMT
UGT1A1  
VKORC1 

Whole blood in EDTA lavender top tube (preferred specimen) 

  • 5.0 mL (optimal); 2.0 mL (minimum)  
  • Room temperature, 2 degrees C to 8 degrees  C for 30 days 

Saliva and buccal swabs are also acceptable 

  • Room temperature, 2 degrees  C to 8 degrees  C 
and -10 degrees  C to -30 degrees C for 30 days 
 7-14 days 
14271 Pharmacogenomics Panel with Coriell Life Sciences 
Read the FAQ

a For medication-specific guidance based on these findings, test code 14271 includes access to a Coriell Life Sciences enhanced report that incorporates drug-gene interaction guidance from curated sources such as CPIC®. Quest does not review or validate Coriell reports. These are developed independently by Coriell’s professional staff.

 

b DNA will be extracted from the sample and tested for changes in multiple genes.

 

References

  1. US Food & Drug Administration (FDA). Preventable adverse drug reactions: a focus on drug interactions. Updated March 6, 2018. Accessed May 29, 2025. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm 
  2. SingleCare Team. Prescription drug statistics 2025. The Checkup. Updated February 4, 2025. SingleCare. Accessed June 24, 2025. https://www.singlecare.com/blog/news/prescription-drug-statistics 
  3. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250(3):186-200. doi:10.1046/j.1365-2796.2001.00879.x
  4. Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017;17(4):301-312. doi:10.1038/tpj.2016.11

 

Test codes may vary by location. Please contact your local laboratory for more information.

Questions?

For direct access to the Genomic Client Services team, call 1.866.GENE.INFO (1.866.436.3463) from 8:30 AM-8:00 PM EST for answers, reports, results interpretation, and post-test consultation.

Contact us

Genetics

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.